For research use only. Not for therapeutic Use.
IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.
The in vitro metabolic stability profiles of IRAK4-IN-1 (Compound 23) is measured, with EC50 of 2300 nM for the rat whole blood (RWB) [1].
Oral pharmacokinetic studies of IRAK4-IN-1 (Compound 23) show it to have high bioavailability of 73% and low plasma clearance
(Clp=22 mL/min/kg) leading to a reasonable half-life of 1.3 h[1].
| Catalog Number | I013071 |
| CAS Number | 1820787-94-7 |
| Synonyms | 4-[(4-morpholin-4-ylcyclohexyl)amino]quinazoline-6-carbonitrile |
| Molecular Formula | C19H23N5O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H23N5O/c20-12-14-1-6-18-17(11-14)19(22-13-21-18)23-15-2-4-16(5-3-15)24-7-9-25-10-8-24/h1,6,11,13,15-16H,2-5,7-10H2,(H,21,22,23) |
| InChIKey | HVQXFGHHSFTACS-UHFFFAOYSA-N |
| SMILES | C1CC(CCC1NC2=NC=NC3=C2C=C(C=C3)C#N)N4CCOCC4 |
| Reference | [1]. Smith GF, et al. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726. |
